Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer

Folia Histochemica et Cytobiologica

Volumn 49, Issue 1, 2011, Pages 125-131

  Mroczko, Barbara ^a   Łukaszewicz Zajac, Marta ^a   Gryko, Mariusz ^a   Kedra, Bogusław ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Gastric cancer; MMP 2; TIMP 2; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STOMACH CANCER; STOMACH WALL;

EID: 79958090922     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0018     Document Type: Article

References (32)

1. Shim K, Jung S, Joo Y, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007;42:120-128.
2. Schwartz G. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol. 1996;23:316-324.
3. Wagenaar-Miller R, Gorden L, Matrisian L. Matrix metallo-proteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004;23:119-135.
4. Bonomi P. Matrix metalloproteinases and matrix metallopro-teinase inhibitors in lung cancer. Semin Oncol. 2002;29:78-86.
5. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix met-alloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002;52:255-264.
6. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugima-chi K. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res. 2000;6:3581-3584.
7. Galis Z, Muszynski M, Sukhova G et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
8. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31:34-45.
9. Kandasamy A, Chow A, Ali M, Schulz R. Matrix metallopro-teinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. 2010;85:413-423.
10. Howard E, Bullen E, Banda M. Preferential inhibition of 72-and 92-kDa gelatinases by tissue inhibitor of metalloprotein-ases-2. J Biol Chem. 1991;266:13070-13075.
11. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15:RA32-RA40.
12. Shin J, Jung S, Kim S et al. Expression of MMP-2, HIF-1al-pha and VEGF in colon adenoma and colon cancer. Korean J Gastroenterol. 2007;50:9-18.
13. Li B, Zhao P, Liu S, Yu Y, Han M, Wen J. Matrix metallopro-teinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroen-terol. 2005;11:3046-3050.
14. Giannopoulos G, Pavlakis K, Parasi A et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008;28:1875-1881.
15. Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2-complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett. 2006;236:125-132.
16. Zheng H, Takahashi H, Murai Y et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579-3583.
17. Wu Z, Li J, Zhan W, He Y. Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol. 2006;12:2941-2944.
18. Mönig S, Baldus S, Hennecken J et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology. 2001;39:597-602.
19. Lochhead P, El-Omar E. Gastric cancer. Br Med Bull. 2008;85:87-100.
20. Samson P, Escovidal L, Yrastorza S, Veneracion R, Nerves M. Re-study of gastric cancer: analysis of outcome. World J Surg. 2002;26:428-433.
21. Alakus H, Grass G, Hennecken J et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol. 2008;23:917-923.
22. Kubben F, Sier C, van Duijn W et al. Matrix metalloprotein-ase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer. 2006;94:1035-1040.
23. Jass JR, LH S. WHO International histological classification of tumors. Histological typing of intestinal tumors. New York: Springer-Verlag, 1989.
24. Mroczko B, Szmitkowski M, Okulczyk B. Granulocyte-colony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in colorectal cancer patients. Clin Chem Lab Med. 2002;40:351-355.
25. Roberts L, Visser J, Ingraham H. Involvement of a matrix metalloproteinase in MIS-induced cell death during uro-genital development. Development. 2002;129:1487-1496.
26. Linask K, Han M, Cai D, Brauer P, Maisastry S. Cardiac morphogenesis: matrix metalloproteinase coordination of cellular mechanisms underlying heart tube formation and directionality of looping. Dev Dyn. 2005;233:739-753.
27. Cho W, Chow A, Schulz R, Daniel E. Matrix metallopro-teinase-2, caveolins, focal adhesion kinase and c-Kit in cells of the mouse myocardium. J Cell Mol Med. 2007;11:1069-1086.
28. Koyama S. Enhanced cell surface expression of matrix metal-loproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci. 2004;49:1621-1630.
29. Waas E, Wobbes T, Ruers T, Lomme R, Hendriks T. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol. 2006;32:756-763.
30. Endo K, Maehara Y, Baba H et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997;17:2253-2258.
31. Mroczko B, Groblewska M, Łukaszewicz-Zajac M, Bandur-ski R, Kedra B, Szmitkowski M. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med. 2009;47:1133-1139.
32. Mroczko B, Wereszczyńska-Siemiatkowska U, Groblewska M et al. The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta. 2006;374:165-167.